K-Ras prenylation as a potential anticancer target
Open accessThe DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Abstract
KRAS is one of the most commonly mutated oncogene and a negative predictive factor for a number of targeted therapies. Therefore, the development of targeting strategies against mutant KRAS is urgently needed. One potential strategy involves disruption of K-Ras membrane localization, which is necessary for its proper function. In this review, we summarize the current data about the importance of membrane-anchorage of K-Ras and provide a critical evaluation of this targeting paradigm focusing mainly on prenylation inhibition. Additionally, we performed a RAS mutation-specific analysis of prenylation-related drug sensitivity data from a publicly available database (https://depmap.org/repurposing/) of three classes of prenylation inhibitors: statins, N-bisphosphonates, and farnesyl-transferase inhibitors. We observed significant differences in sensitivity to N-bisphosphonates and farnesyl-transferase inhibitors depending on KRAS mutational status and tissue of origin. These observations emphasize the importance of factors affecting efficacy of prenylation inhibition, like distinct features of different KRAS mutations, tissue-specific mutational patterns, K-Ras turnover, and changes in regulation of prenylation process. Finally, we enlist the factors that might be responsible for the large discrepancy between the outcomes in preclinical and clinical studies including methodological pitfalls, the incomplete understanding of K-Ras protein turnover, and the variation of KRAS dependency in KRAS mutant tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 3 Drug sensitivity values from PRISM repurposing primary screen of all cell lines independent of tissue of origins. Efficacy of statins, nitrogen-containing bisphosphonates, and farnesyl-transferase inhibitors on KRAS mutant cells versus RAS wild-type cell lines are showed by analyzing the open access data from [52]. Drugs included for the analyses are listed in Table 2. KRAS mutant cell lines were more resistant to statins (RAS WT mean − 0.123, SEM 0.024; KRAS MUT mean – 0.176, SEM 0.040), while the opposite can be observed in response to N-bisphosphonate treatment (RAS WT mean – 0.124, SEM 0.010; KRAS MUT mean − 0.176, SEM 0.022). Statistical significance was established in p < 0.05, using two-tailed t test. Number of cell lines included in the analyses RAS WT n ~ 390; KRAS MUT n ~ 103 (there is a small variation between the numbers of cell lines with available data for the distinct drugs)](https://figures.cochat.ai/paper-figures/c50748e2be484c38b98779b080b61e84/k-ras-prenylation-as-a-potential-anticancer-target-figure-3.jpg)
![Fig. 4 Drug sensitivity values from PRISM repurposing primary screen of lung and colorectal cancer cells. Efficacy of statins, nitrogene-containing bisphosphonates, and farnesyl-transferase inhibitors on KRAS mutant cells versus RAS wild-type cell lines are showed. List of drugs included for the analyses are listed in Table 2. Interestingly, statistically significant difference could only be observed in lung cancer cell lines treated with FTis (RAS WT mean – 0.021, SEM 0.076; KRAS MUT mean – 0.385, SEM 0.117). Note the opposite trends in sensitivity between N-bisphosphonate- and FTi-treated colorectal and lung cancer cells. Statistical significance was established in p < 0.05, using two-tailed t test. n analysis was performed using the open access data of [52]. Number of cell lines included in the analyses for colorectal cancer cell lines: RAS WT n ~ 10; KRAS MUT n ~ 20; for lung adenocarcinomas: RAS WT n ~ 28; KRAS MUT n ~ 18. There is a small variation between the number of cell lines with available data for the distinct drugs](https://figures.cochat.ai/paper-figures/c3cf2021286d4a24bb401fc8973f7584/k-ras-prenylation-as-a-potential-anticancer-target-figure-4.jpg)
![Fig. 5 Drug sensitivity values from PRISM repurposing primary screen of lung and colorectal cancer cells. Efficacy of farnesyl-transferase inhibitors (tipifarnib and lonafarnib) on HRAS mutant cells versus RAS wild-type cell lines is presented. A strong tendency was observed, HRAS mutant cells were more sensitive to FTi treatment than RAS wild-type cells (RAS WT mean – 0.178, SEM 0.026; HRAS MUT mean – 0.554, SEM 0.243). p value was calculated using two-tailed t test. The open access data of [52] was used for the analysis. Number of cell lines included in the analyses: RAS WT n = 396; HRAS MUT n = 7 (created by Graphpad Prism 5 software)](https://figures.cochat.ai/paper-figures/fab2e8c3a4154f919e05a7d13c018caf/k-ras-prenylation-as-a-potential-anticancer-target-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Inhibiting plasma membrane KRAS localization using farnesyltransferase inhibitors suppressed MAPK activity, showing an antitumor effect on cancers driven by KRAS mutations43,44.”
From Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization (2025) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 4×
“These mutations impair the ability of GAP proteins to facilitate hydrolyses of GTP to GDP, and therefore the proteins will be constitutively in active, GTP-bound state [1].”
BackgroundInfluentialGEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Hancock, J. F., Paterson, H., & Marshall, C. J. (1990) · Cell · doi:10.1016/0092-8674(90)90294-o · Cited by 1,059 · cited 1×
“However, K-Ras4b contains an isoform-specific polybasic sequence in the HVR, which fosters association to the acidic regions of the plasma membrane (PM) [23].”
BackgroundRAS isoforms and mutations in cancer at a glance
Hobbs, G. A., Der, C. J., & Rossman, K. L. (2016) · Journal of Cell Science · doi:10.1242/jcs.182873 · Cited by 973
K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors
Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishop, W. R., & Pai, J.-K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14459 · Cited by 884 · cited 9×
“While K-Ras4a—as N- and H-Ras—is subjected to another lipid modification, named palmytoilation, K-Ras4b can only undergo prenylation [22].”
BackgroundInfluentialDiscovering the anticancer potential of non-oncology drugs by systematic viability profiling
Corsello, S. M., Nagari, R. T., Spangler, R. D., Rossen, J., Kocak, M., Bryan, J. G., Humeidi, R., Peck, D., Wu, X., Tang, A. A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0018-6 · Cited by 878 · cited 5×
“The open access data of [52] was used for the analysis.”
BackgroundMethodInfluentialThe relation between PI3K/AKT signalling pathway and cancer
Noorolyai, S., Shajari, N., Baghbani, E., Sadreddini, S., & Baradaran, B. (2019) · Gene · doi:10.1016/j.gene.2019.02.076 · Cited by 651
Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S. A., Triola, G., Wittinghofer, A., Bastiaens, P. I. H., et al. (2013) · Nature · doi:10.1038/nature12205 · Cited by 596 · cited 6×
“By computational modeling and experimental data, Schmick and colleagues demonstrated that—Pde6δ can extract K-Ras4b from the membranes.”
BackgroundInfluentialProtein prenylation: unique fats make their mark on biology
Wang, M., & Casey, P. J. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.11 · Cited by 547
K-ras is an essential gene in the mouse with partial functional overlap with N-ras
Johnson, L., Greenbaum, D., Cichowski, K., Mercer, K., Murphy, E., Schmitt, E., Bronson, R. T., Umanoff, H., Edelmann, W., Kucherlapati, R., et al. (1997) · Genes & Development · doi:10.1101/gad.11.19.2468 · Cited by 545
A dimerization-dependent mechanism drives RAF catalytic activation
Rajakulendran, T., Sahmi, M., Lefrançois, M., Sicheri, F., & Therrien, M. (2009) · Nature · doi:10.1038/nature08314 · Cited by 489
Ras Isoforms Vary in Their Ability to Activate Raf-1 and Phosphoinositide 3-Kinase
Yan, J., Roy, S., Apolloni, A., Lane, A., & Hancock, J. F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.37.24052 · Cited by 477
Safety and efficacy of statin therapy
Adhyaru, B. B., & Jacobson, T. A. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0098-5 · Cited by 424
Bisphosphonates: Preclinical Review
Green, J. R. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90004-3 · Cited by 405
Modulation of Ras and a-Factor Function by Carboxyl-Terminal Proteolysis
Boyartchuk, V. L., Ashby, M. N., & Rine, J. (1997) · Science · doi:10.1126/science.275.5307.1796 · Cited by 361
K-Ras is essential for the development of the mouse embryo
Koera, K., Nakamura, K., Nakao, K., Miyoshi, J., Toyoshima, K., Hatta, T., Otani, H., Aiba, A., & Katsuki, M. (1997) · Oncogene · doi:10.1038/sj.onc.1201284 · Cited by 355
A tagging-via-substrate technology for detection and proteomics of farnesylated proteins
Kho, Y., Kim, S. C., Jiang, C., Barma, D., Kwon, S. W., Cheng, J., Jaunbergs, J., Weinbaum, C., Tamanoi, F., Falck, J., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403413101 · Cited by 327
Tissue-specific tumorigenesis: context matters
Schneider, G., Schmidt-Supprian, M., Rad, R., & Saur, D. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.5 · Cited by 311
Lipid rafts as major platforms for signaling regulation in cancer
Mollinedo, F., & Gajate, C. (2015) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.10.003 · Cited by 308
Esteban, L. M., Vicario-Abejón, C., Fernández-Salguero, P., Fernández-Medarde, A., Swaminathan, N., Yienger, K., Lopez, E., Malumbres, M., McKay, R., Ward, J. M., et al. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1444-1452.2001 · Cited by 298
Voice, J. K., Klemke, R. L., Le, A., & Jackson, J. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.17164 · Cited by 288
Inhibition of RAS function through targeting an allosteric regulatory site
Spencer-Smith, R., Koide, A., Zhou, Y., Eguchi, R. R., Sha, F., Gajwani, P., Santana, D., Gupta, A., Jacobs, M., Herrero-Garcia, E., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2231 · Cited by 283 · cited 1×
“Moreover, blocking K-Ras dimerization and nanoclustering—either by genetic means or with specific antibodies—inhibits the efficacy of BRaf/CRaf heterodimerization and MAP kinase (MAPK) activation [33, 34].”
BackgroundRas-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway
Nan, X., Tamgüney, T. M., Collisson, E. A., Lin, L.-J., Pitt, C., Galeas, J., Lewis, S., Gray, J. W., McCormick, F., & Chu, S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1509123112 · Cited by 273
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
Ambrogio, C., Köhler, J., Zhou, Z.-W., Wang, H., Paranal, R., Li, J., Capelletti, M., Caffarra, C., Li, S., Lv, Q., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.020 · Cited by 270 · cited 3×
“Moreover, blocking K-Ras dimerization and nanoclustering—either by genetic means or with specific antibodies—inhibits the efficacy of BRaf/CRaf heterodimerization and MAP kinase (MAPK) activation [33, 34].”
BackgroundGrowth factor receptors, lipid rafts and caveolae: An evolving story
Pike, L. J. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2005.05.005 · Cited by 269
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Misale, S., Fatherree, J. P., Cortez, E., Li, C., Bilton, S., Timonina, D., Myers, D. T., Lee, D., Gomez-Caraballo, M., Greenberg, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0368 · Cited by 259
Kimmel, D. B. (2007) · Journal of Dental Research · doi:10.1177/154405910708601102 · Cited by 251 · cited 1×
“bones limiting their use to bone-related diseases like osteoporosis or bone metastases [47].”
BackgroundSchmick, M., Vartak, N., Papke, B., Kovacevic, M., Truxius, D. C., Rossmannek, L., & Bastiaens, P. I. H. (2014) · Cell · doi:10.1016/j.cell.2014.02.051 · Cited by 243
The murine N-ras gene is not essential for growth and development.
Umanoff, H., Edelmann, W., Pellicer, A., & Kucherlapati, R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1709 · Cited by 234
Buday, L., & Downward, J. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.05.001 · Cited by 230
Self-citationK-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif
Tsai, F. D., Lopes, M. S., Zhou, M., Court, H., Ponce, O., Fiordalisi, J. J., Gierut, J. J., Cox, A. D., Haigis, K. M., & Philips, M. R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412811112 · Cited by 226
Jeong, W.-J., Ro, E. J., & Choi, K.-Y. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0049-y · Cited by 220
Mapping the Nucleotide and Isoform-Dependent Structural and Dynamical Features of Ras Proteins
Gorfe, A. A., Grant, B. J., & McCammon, J. A. (2008) · Structure · doi:10.1016/j.str.2008.03.009 · Cited by 216
Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination
Steklov, M., Pandolfi, S., Baietti, M. F., Batiuk, A., Carai, P., Najm, P., Zhang, M., Jang, H., Renzi, F., Cai, Y., et al. (2018) · Science · doi:10.1126/science.aap7607 · Cited by 215 · cited 1×
“Many mechanism has been proposed to regulate K-Ras degradation, including Lztr1-cul3 [63], Nedd41 [64], and βTrcp1 [65].”
BackgroundYoung, A., Lou, D., & McCormick, F. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0231 · Cited by 211 · cited 1×
“PI3K-Erk crosstalk [69], impaired upstream signals or regulatory feedback loop activation [70] can greatly affect phosphorylation of Erk; thus, it is always necessary to perform other validation experiments for mechanistic conclusions.”
Zhang, F. L., Kirschmeier, P., Carr, D., James, L., Bond, R. W., Wang, L., Patton, R., Windsor, W. T., Syto, R., Zhang, R., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.15.10232 · Cited by 197 · cited 11×
“Palmytoilation happens in the endomembranes—in the Golgi apparatus—and fosters vesicular transport of K-Ras4a to the plasma membrane.”
BackgroundInfluentialRas-Mediated Activation of the Raf Family Kinases
Terrell, E. M., & Morrison, D. K. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a033746 · Cited by 190
Irwin, M. E., Mueller, K. L., Bohin, N., Ge, Y., & Boerner, J. L. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22570 · Cited by 181
Survival of pancreatic cancer cells lacking KRAS function
Muzumdar, M. D., Chen, P.-Y., Dorans, K. J., Chung, K. M., Bhutkar, A., Hong, E., Noll, E. M., Sprick, M. R., Trumpp, A., & Jacks, T. (2017) · Nature Communications · doi:10.1038/s41467-017-00942-5 · Cited by 177
CAAX Geranylgeranyl Transferase Transfers Farnesyl as Efficiently as Geranylgeranyl to RhoB
Armstrong, S. A., Hannah, V. C., Goldstein, J. L., & Brown, M. S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.14.7864 · Cited by 164
The kidney and bisphosphonates
Miller, P. D. (2011) · Bone · doi:10.1016/j.bone.2010.12.024 · Cited by 164
Cholesterol and beyond - The role of the mevalonate pathway in cancer biology
Göbel, A., Rauner, M., Hofbauer, L. C., & Rachner, T. D. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188351 · Cited by 164
Loboda, A., Nebozhyn, M., Klinghoffer, R., Frazier, J., Chastain, M., Arthur, W., Roberts, B., Zhang, T., Chenard, M., Haines, B., et al. (2010) · BMC Medical Genomics · doi:10.1186/1755-8794-3-26 · Cited by 152
The effect of statins on cancer cells—review
Matusewicz, L., Meissner, J. M., Toporkiewicz, M., & Sikorski, A. F. (2015) · Tumor Biology · doi:10.1007/s13277-015-3551-7 · Cited by 149
Rare Codons Regulate KRas Oncogenesis
Lampson, B. L., Pershing, N. L. K., Prinz, J. A., Lacsina, J. R., Marzluff, W. F., Nicchitta, C. V., MacAlpine, D. M., & Counter, C. M. (2013) · Current Biology · doi:10.1016/j.cub.2012.11.031 · Cited by 148
Potenza, N., Vecchione, C., Notte, A., Rienzo, A. D., Rosica, A., Bauer, L., Affuso, A., Felice, M. D., Russo, T., Poulet, R., et al. (2005) · EMBO Reports · doi:10.1038/sj.embor.7400397 · Cited by 145
Jiménez, C., Hernández, C., Pimentel, B., & Carrera, A. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205893200 · Cited by 143
N-terminal Protein Processing: A Comparative Proteogenomic Analysis
Bonissone, S. R., Gupta, N., Romine, M. F., Bradshaw, R. A., & Pevzner, P. A. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.019075 · Cited by 115
Sethi, M. K., Kim, H., Park, C. K., Baker, M. S., Paik, Y., Packer, N. H., Hancock, W. S., Fanayan, S., & Thaysen‐Andersen, M. (2015) · Glycobiology · doi:10.1093/glycob/cwv042 · Cited by 108 · cited 1×
“Altered glycosylation of EGFR has been shown in colorectal cancer samples compared to adjacent normal tissue [92].”
BackgroundWelle, K. A., Zhang, T., Hryhorenko, J. R., Shen, S., Qu, J., & Ghaemmaghami, S. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.063230 · Cited by 100
Zoledronic Acid -a Multiplicity of Anti-Cancer Action
Yuasa, T., Kimura, S. H., Ashihara, E., Habuchi, T., & Maekawa, T. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707781389600 · Cited by 99
Role of N‐glycosylation in EGFR ectodomain ligand binding
Irani, M. A., Kannan, S., & Verma, C. S. (2017) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25314 · Cited by 99
KRAS Protein Stability Is Regulated through SMURF2: UBCH5 Complex-Mediated β-TrCP1 Degradation
Shukla, S., Allam, U. S., Ahsan, A., Chen, G., Krishnamurthy, P. M., Marsh, K., Rumschlag, M., Shankar, S., Whitehead, C., Schipper, M., et al. (2014) · Neoplasia · doi:10.1593/neo.14184 · Cited by 96 · cited 2×
“Unfortunately, no reliable data are currently available on K-Ras protein turnover except for some sporadic reports that not allow exact determination of dynamics of degradation and synthesis rates [65, 80].”
BackgroundImpeded Nedd4-1-Mediated Ras Degradation Underlies Ras-Driven Tumorigenesis
Zeng, T., Wang, Q., Fu, J., Lin, Q., Bi, J., Ding, W., Qiao, Y., Zhang, S., Zhao, W., Lin, H., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.045 · Cited by 94
Ras and the Plasma Membrane: A Complicated Relationship
Zhou, Y., Prakash, P., Gorfe, A. A., & Hancock, J. F. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031831 · Cited by 86 · cited 1×
“Of note, several studies indicated that K-Ras localization is not homogenous at the plasma membrane, rather it appears to signal through nanoclusters, small groups of Ras proteins at distinct compartments part of the plasma membrane [32].”
BackgroundPosttranslational Modifications of RAS Proteins
Ahearn, I., Zhou, M., & Philips, M. R. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031484 · Cited by 86 · cited 1×
“While K-Ras4a—as N- and H-Ras—is subjected to another lipid modification, named palmytoilation, K-Ras4b can only undergo prenylation [22].”
BackgroundWaller, D. D., Park, J., & Tsantrizos, Y. S. (2019) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2019.1568964 · Cited by 86
Li, S., Jang, H., Zhang, J., & Nussinov, R. (2018) · Structure · doi:10.1016/j.str.2018.01.011 · Cited by 79 · cited 1×
“Moreover, Raf cysteine-rich domains (CRD) have been shown to promote Raf membrane association which in concert with Ras binding, stabilizes the signaling complex at the PM, and probably facilitate signaling by reducing the Ras-Rafbinding fluctuations [36].”
BackgroundThe Key Role of Calmodulin in KRAS-Driven Adenocarcinomas
Nussinov, R., Muratcioglu, S., Tsai, C.-J., Jang, H., Gursoy, A., & Keskin, O. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0165 · Cited by 78
Lohinai, Z., Klikovits, T., Moldvay, J., Ostoros, G., Raso, E., Timar, J., Fabian, K., Kovalszky, I., Kenessey, I., Aigner, C., et al. (2017) · Scientific Reports · doi:10.1038/srep39721 · Cited by 78
Self-citationKuijpers, C. C. H. J., Hendriks, L. E. L., Derks, J. L., Dingemans, A. C., van Lindert, A. S. R., van den Heuvel, M. M., Damhuis, R. A. M., & Willems, S. M. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.05.006 · Cited by 73
Mitrofan, L. M., Pelkonen, J., & Mönkkönen, J. (2009) · Bone · doi:10.1016/j.bone.2009.08.010 · Cited by 65 · cited 1×
“One documented mechanism of action that can be different between statins and N-bisphosphonates is that the latter—by inhibiting IPP conversion to farnesyl-PP— facilitates accumulation of IPP that in turn will be conjugated to AMP resulting in cytotoxic ATP analogue ApppI [42].”
BackgroundSantolaria, T., Robard, M., Léger, A., Catros, V., Bonneville, M., & Scotet, E. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300255 · Cited by 61 · cited 1×
“Furthermore, N-bisphosphonates can alsomodulate tumor microenvironment, for example, zoledronic acid has been shown to activate γδT cells [72], or modulate tumor xenograft vas-”
BackgroundEvaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies
Waters, A. M., Ozkan-Dagliyan, I., Vaseva, A. V., Fer, N., Strathern, L. A., Hobbs, G. A., Tessier-Cloutier, B., Gillette, W. K., Bagni, R., Whiteley, G. R., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aao3332 · Cited by 61 · cited 1×
“could lead to false results and conclusions [68].”
Tew, G. W., Lorimer, E. L., Berg, T. J., Zhi, H., Li, R., & Williams, C. L. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707526200 · Cited by 60
The clinical relevance of KRAS gene mutation in non-small-cell lung cancer
Tímár, J. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000051 · Cited by 59
Quantification of spatiotemporal patterns of Ras isoform expression during development
Newlaczyl, A. U., Coulson, J. M., & Prior, I. A. (2017) · Scientific Reports · doi:10.1038/srep41297 · Cited by 58
Alawin, O. A., Ahmed, R. A., Ibrahim, B. A., Briski, K. P., & Sylvester, P. W. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.09.018 · Cited by 57
Freije, J. M. P., Blay, P., Pendás, A. M., Cadiñanos, J., Crespo, P., & López-Otı́n, C. (1999) · Genomics · doi:10.1006/geno.1999.5834 · Cited by 57
Post translational modifications of Rab GTPases
Shinde, S. R., & Maddika, S. (2017) · Small GTPases · doi:10.1080/21541248.2017.1299270 · Cited by 56
Hibino, K., Shibata, T., Yanagida, T., & Sako, Y. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.262675 · Cited by 55
Xia, Y., Liu, Y.-L., Xie, Y., Zhu, W., Guerra, F., Shen, S., Yeddula, N., Fischer, W., Low, W., Zhou, X., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3010382 · Cited by 55
Targeting the RAS-dependent chemoresistance: The Warburg connection
Serna-Blasco, R., Sanz-Álvarez, M., Aguilera, Ó., & García-Foncillas, J. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.016 · Cited by 52
KRAS Prenylation Is Required for Bivalent Binding with Calmodulin in a Nucleotide-Independent Manner
Agamasu, C., Ghirlando, R., Taylor, T., Messing, S., Tran, T. H., Bindu, L., Tonelli, M., Nissley, D. V., McCormick, F., & Stephen, A. G. (2019) · Biophysical Journal · doi:10.1016/j.bpj.2019.02.004 · Cited by 51
Site-Specific Quantification of Surface N-Glycoproteins in Statin-Treated Liver Cells
Xiao, H., Tang, G. X., & Wu, R. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.5b04871 · Cited by 47
β‐Catenin‐ RAS interaction serves as a molecular switch for RAS degradation via GSK 3β
Lee, S., Jeong, W., Cho, Y., Cha, P., Yoon, J., Ro, E. J., Choi, S., Oh, J., Heo, Y., Kim, H., et al. (2018) · EMBO reports · doi:10.15252/embr.201846060 · Cited by 44
How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization
J. Brock, E., Ji, K., J. Reiners, J., & R. Mattingly, R. (2016) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666151001154002 · Cited by 40
Intrinsic GTPase activity of K-RAS monitored by native mass spectrometry
Moghadamchargari, Z., Huddleston, J., Shirzadeh, M., Zheng, X., Clemmer, D. E., M. Raushel, F., Russell, D. H., & Laganowsky, A. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00532 · Cited by 38
Phosphorylation weakens but does not inhibit membrane binding and clustering of K-Ras4B
Zhang, S.-Y., Sperlich, B., Li, F.-Y., Al-Ayoubi, S., Chen, H.-X., Zhao, Y.-F., Li, Y.-M., Weise, K., Winter, R., & Chen, Y.-X. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00165 · Cited by 36
KRAS-Mutant Lung Cancers in the Era of Targeted Therapy
Naidoo, J., & Drilon, A. E. D. C. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24223-1_8 · Cited by 34
Isoform-specific Ras signaling is growth factor dependent
Hood, F. E., Klinger, B., Newlaczyl, A. U., Sieber, A., Dorel, M., Oliver, S. P., Coulson, J. M., Blüthgen, N., & Prior, I. A. (2019) · Molecular Biology of the Cell · doi:10.1091/mbc.e18-10-0676 · Cited by 34
Splice switching an oncogenic ratio of SmgGDS isoforms as a strategy to diminish malignancy
Brandt, A. C., McNally, L. M., Lorimer, E., Unger, B., Koehn, O. J., Suazo, K. F., Rein, L., Szabó, A., Tsaih, S., Distefano, M. D., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914153117 · Cited by 30
Ghimessy, Á. K., Gellert, Á., Schlegl, E., Hegedus, B., Raso, E., Barbai, T., Timar, J., Ostoros, G., Megyesfalvi, Z., Gieszer, B., et al. (2019) · Cancers · doi:10.3390/cancers11101514 · Cited by 27
Self-citationGaray, T., Kenessey, I., Molnár, E., Juhász, É., Réti, A., László, V., Rózsás, A., Dobos, J., Döme, B., Berger, W., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117021 · Cited by 26
Self-citationSmgGDS-558 regulates the cell cycle in pancreatic, non-small cell lung, and breast cancers
Schuld, N. J., Hauser, A. D., Gastonguay, A. J., Wilson, J. M., Lorimer, E., & Williams, C. L. (2014) · Cell Cycle · doi:10.4161/cc.27804 · Cited by 23
Rittler, D., Baranyi, M., Molnár, E., Garay, T., Jalsovszky, I., Varga, I. K., Hegedüs, L., Aigner, C., Tóvári, J., Tímár, J., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194917 · Cited by 19
Self-citationKenessey, I., Kói, K., Horváth, O. N., Cserepes, M., Molnár, D., Izsák, V. D., Dobos, J., Hegedűs, B., Tóvári, J., & Tímár, J. (2016) · Oncotarget · doi:10.18632/oncotarget.12806 · Cited by 17 · cited 1×
“Furthermore, N-bisphosphonates can alsomodulate tumor microenvironment, for example, zoledronic acid has been shown to activate γδT cells [72], or modulate tumor xenograft vascularization [73].”
BackgroundSelf-citationBaranyi, M., Rittler, D., Molnár, E., Shirasawa, S., Jalsovszky, I., Varga, I. K., Hegedüs, L., Németh, A., Dank, M., Aigner, C., et al. (2020) · Pathology & Oncology Research · doi:10.1007/s12253-019-00789-9 · Cited by 16 · cited 2×
“Furthermore, recently developed lipophil ic Nbisphosphonates are also potential applicants for targeting even non-bone-related KRAS mutant tumors [48, 71].”
BackgroundSelf-citationThe role of lipid signaling in the progression of malignant melanoma
Tímár, J., Hegedűs, B., & Rásó, E. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9729-x · Cited by 15
Self-citationAmissah, F., Taylor, S., Duverna, R., Ayuk‐Takem, L. T., & Lamango, N. S. (2011) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.201100030 · Cited by 11
KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence
Tı́már, J., Hegedűs, B., & Rásó, E. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910793357989 · Cited by 11
Self-citationKanaji, N., Tadokoro, A., Watanabe, N., Inoue, T., Kadowaki, N., & Ishii, T. (2019) · Respiratory Investigation · doi:10.1016/j.resinv.2019.06.004 · Cited by 10
Cited by
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma
Moon, H., & Ro, S. W. (2021) · Cancers · doi:10.3390/cancers13123026 · Cited by 326
“Thus, targeting the farnesylation pathway has attracted significant attention as a therapeutic strategy to inhibit RAS and subsequently suppress the MAPK/ERK signaling cascades [137,138].”
BackgroundThe RASopathies: from pathogenetics to therapeutics
Hebron, K. E., Hernandez, E. R., & Yohe, M. E. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049107 · Cited by 167
“Either statins or N-bisphosphonates, then, might prevent RAS prenylation and, thus, its activation in patients with RASopathies (Baranyi et al., 2020).”
BackgroundBeyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer
Morofuji, Y., Nakagawa, S., Ujifuku, K., Fujimoto, T., Otsuka, K., Niwa, M., & Tsutsumi, K. (2022) · Pharmaceuticals · doi:10.3390/ph15020151 · Cited by 151
“Several previous reports have indicated that statin-mediated Ras suppression regulates cellular proliferation and cell death, consequently leading to an antitumor effect [38,39].”
BackgroundComputational drug repurposing: approaches, evaluation of in silico resources and case studies
Tanoli, Z., Fernández‐Torras, A., Özcan, U. O., Kushnir, A., Nader, K. M., Gadiya, Y., Fiorenza, L., Ianevski, A., Vähä-Koskela, M. J. V., Miihkinen, M., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01164-x · Cited by 123
“Through linking genomic annotations with the PRISM drug sensitivity profiles 110 , Baranyi et al. 111 found that cellular responses to clinically approved prenylation inhibitors depend on KRAS mutational status and tissue”
Roles of Farnesyl-Diphosphate Farnesyltransferase 1 in Tumour and Tumour Microenvironments
Hà, N. T. T., & Lee, C. H. (2020) · Cells · doi:10.3390/cells9112352 · Cited by 80
Metadata
- Authors
- Baranyi, M., Buday, L., & Hegedűs, B.
- Affiliations
- Semmelweis University (HU)
- Institute of Molecular Life Sciences (HU)
- Ruhrlandklinik (DE)
- Corresponding author
- Hegedűs, Balázs
- Venue
- Cancer and Metastasis Reviews
- Published
- 2020-06-10
- Volume
- 39
- Issue
- 4
- Pages
- 1127-1141
- ISSN
- 0167-7659 (ISSN-L)
- 1573-7233
- PMC
- PMC7680335
- OpenAlex
- W3033488157
- Cited by
- 62
- References
- 94
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 13 · 2023: 7 · 2022: 6 · 2021: 7 · 2020: 4
- FWCI
- 0.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cancer and Metastasis Reviews (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- Funders
- Hungarian National Research, Development and Innovation Office (NVKP-16-1-2016-0020)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- KRAS, membrane anchorage, KRAS mutation, farnesyltransferase inhibitors, statins, drug repurposing, anticancer drug targets, KRAS-mutant tumors
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Protein Processing, Post-Translational, Genes, ras, Proto-Oncogene Proteins p21(ras), Prenylation, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.